

TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY CYTOKINE
INHIBITORS INTO ORTHOPEDIC JOINTS

ABSTRACT OF THE DISCLOSURE

- 5 The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of:
- 10 i) an inhibitor of a pro-inflammatory interleukin;
 ii) an inhibitor of TNF- α synthesis;
 iii) an inhibitor of membrane-bound TNF- α ;
 iv) an inhibitor of a natural receptor of TNF- α ;
 v) an inhibitor of NO synthase,
 vi) an inhibitor of PLA₂ enzyme;
 vii) an anti-proliferative agent;
 viii) an anti-oxidant;
- 15 ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-I, IGF-II, and caspase inhibitors, and
 x) an inhibitor of MMPs; and
- 20 xi) an inhibitor of p38 kinase.